Cardiol Therapeutics Inc Class A (TO:CRDL) — Stock Price
Cardiol Therapeutics Inc Class A (TO:CRDL) is currently trading at CA$2.06 CAD, up 3.52% today. Over the past 52 weeks, shares have ranged between CA$1.28 and CA$2.23. This page tracks Cardiol Therapeutics Inc Class A's live share price on the TO exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Cardiol Therapeutics Inc Class A stock valuation.
Cardiol Therapeutics Inc Class A (CRDL) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Cardiol Therapeutics Inc Class A's daily closing share price and trading volume on the TO exchange over the past year, giving a clear view of recent price momentum and liquidity.
Cardiol Therapeutics Inc Class A Income Statement — Revenue, Profit & Earnings by Year
Cardiol Therapeutics Inc Class A's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | CA$0.00 | CA$0.00 | CA$0.00 | CA$0.00 | CA$78.76K |
| Cost of Revenue | — | CA$373.11K | CA$248.35K | CA$219.91K | — |
| Gross Profit | — | CA$-373.11K | CA$-248.35K | CA$-219.91K | CA$78.76K |
| Research & Development | CA$14.02 Million | CA$14.01 Million | CA$14.22 Million | CA$18.96 Million | CA$10.87 Million |
| SG&A | CA$20.20 Million | CA$26.26 Million | CA$15.56 Million | CA$22.37 Million | CA$27.87 Million |
| Total Operating Expenses | CA$34.32 Million | CA$39.90 Million | CA$29.54 Million | CA$41.34 Million | CA$38.74 Million |
| Operating Income | CA$-34.32 Million | CA$-40.28 Million | CA$-29.79 Million | CA$-50.34 Million | CA$-45.47 Million |
| EBITDA | CA$-34.21 Million | CA$-36.30 Million | CA$-27.88 Million | CA$-30.71 Million | CA$-38.44 Million |
| EBIT | CA$-34.32 Million | CA$-36.68 Million | CA$-28.13 Million | CA$-30.93 Million | CA$-38.66 Million |
| Interest Expense | — | — | — | CA$19.41 Million | CA$106.00K |
| Income Before Tax | CA$-33.82 Million | CA$-36.68 Million | CA$-28.13 Million | CA$-30.93 Million | CA$-31.64 Million |
| Income Tax Expense | — | — | CA$5.00 | CA$-19.41 Million | CA$-6.91 Million |
| Net Income | CA$-33.82 Million | CA$-36.68 Million | CA$-28.13 Million | CA$-11.52 Million | CA$-24.72 Million |
Cardiol Therapeutics Inc Class A Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Cardiol Therapeutics Inc Class A's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | CA$23.62 Million | CA$31.86 Million | CA$36.70 Million | CA$62.03 Million | CA$87.88 Million |
| Total Current Assets | CA$23.50 Million | CA$31.67 Million | CA$36.15 Million | CA$61.44 Million | CA$87.14 Million |
| Cash & Equivalents | CA$21.42 Million | CA$30.58 Million | CA$34.93 Million | CA$59.47 Million | CA$83.90 Million |
| Short-term Investments | — | — | CA$61.88K | CA$61.88K | CA$61.57K |
| Net Receivables | CA$226.19K | CA$361.62K | CA$279.87K | CA$480.20K | CA$407.13K |
| Inventory | — | — | — | — | CA$339.05K |
| Property, Plant & Equipment | CA$118.09K | CA$195.59K | CA$337.06K | CA$295.74K | CA$356.49K |
| Goodwill | — | — | — | — | — |
| Total Liabilities | CA$5.74 Million | CA$7.14 Million | CA$8.45 Million | CA$9.83 Million | CA$11.64 Million |
| Total Current Liabilities | CA$5.66 Million | CA$7.01 Million | CA$8.30 Million | CA$9.80 Million | CA$11.57 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | CA$-21.29 Million | CA$-30.42 Million | CA$-34.77 Million | CA$-59.40 Million | CA$-83.78 Million |
| Total Stockholder Equity | CA$17.88 Million | CA$24.73 Million | CA$28.25 Million | CA$52.20 Million | CA$76.24 Million |
| Retained Earnings | CA$-213.07 Million | CA$-179.25 Million | CA$-142.58 Million | CA$-114.45 Million | CA$-83.52 Million |
Cardiol Therapeutics Inc Class A Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Cardiol Therapeutics Inc Class A generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | CA$-23.85 Million | CA$-25.06 Million | CA$-25.18 Million | CA$-27.22 Million | CA$-23.55 Million |
| Capital Expenditures | CA$24.48K | CA$21.29K | CA$64.31 | CA$74.71K | CA$12.92K |
| Free Cash Flow | CA$-23.88 Million | CA$-25.08 Million | CA$-25.24K | CA$-27.30 Million | CA$-23.56 Million |
| Investing Cash Flow | CA$-24.48K | CA$-21.29K | CA$-64.31K | CA$-74.71K | CA$-12.92K |
| Financing Cash Flow | CA$15.54 Million | CA$18.84 Million | CA$-55.38K | CA$-53.93K | CA$93.44 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | CA$10.70 Million | CA$14.28 Million | CA$4.17 Million | CA$5.01 Million | CA$8.50 Million |
| Depreciation | CA$101.98K | CA$373.11K | CA$248.35K | CA$219.91K | CA$220.42K |
| Change in Cash | CA$-9.16 Million | CA$-4.35 Million | CA$-24.54 Million | CA$-24.43 Million | CA$69.87 Million |
Cardiol Therapeutics Inc Class A Earnings History — EPS Actual vs. Analyst Estimates
Track Cardiol Therapeutics Inc Class A's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 12, 2026 | -0.07 | — | — |
| Mar 31, 2026 | -0.07 | -0.11 | +36.36% |
| Nov 13, 2025 | -0.12 | -0.10 | -20.00% |
| Aug 14, 2025 | -0.10 | -0.12 | +16.67% |
| May 14, 2025 | -0.10 | -0.13 | +23.08% |
| Mar 31, 2025 | -0.09 | -0.12 | +22.88% |
| Nov 14, 2024 | -0.18 | -0.11 | -63.64% |
| Aug 12, 2024 | -0.10 | -0.13 | +23.08% |